Skip to main
CMPS

COMPASS Pathways (CMPS) Stock Forecast & Price Target

COMPASS Pathways (CMPS) Analyst Ratings

Based on 12 analyst ratings
Buy
Strong Buy 58%
Buy 33%
Hold 8%
Sell 0%
Strong Sell 0%

Bulls say

Compass Pathways is expected to have a successful launch of their COMP360 treatment due to promising trial results, increased commercial preparation, and the potential for a parallel DEA rescheduling. With a funded runway into 2028 and a targeted population of 4 million in the US alone, Compass Pathways is poised for potential success in the mental health biotechnology industry. Though risks such as clinical development, competition, and regulatory hurdles exist, the company's strong financial position and promising data make it a favorable investment.

Bears say

Compass Pathways is facing potential roadblocks in launching their drug, COMP360, as its lengthy treatment process may not be accepted by providers and patient demand for psychedelics is robust, leading to uncertain peak commercial potential. Furthermore, the company faces competition from other players in the emerging psychedelics market, and their late-stage PTSD program may not offer significant upside. This combined with a discounted cash flow analysis with a low terminal growth rate suggests a negative outlook for the company's stock.

COMPASS Pathways (CMPS) has been analyzed by 12 analysts, with a consensus rating of Buy. 58% of analysts recommend a Strong Buy, 33% recommend Buy, 8% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of COMPASS Pathways and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About COMPASS Pathways (CMPS) Forecast

Analysts have given COMPASS Pathways (CMPS) a Buy based on their latest research and market trends.

According to 12 analysts, COMPASS Pathways (CMPS) has a Buy consensus rating as of Aug 29, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $23.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $23.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

COMPASS Pathways (CMPS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.